SCHEMBL30206027

SCHEMBL30206027

COC(=O)c1nc(-c2cccc3c2ncn3C)c(C)nc1Nc1ccc(N2CCOCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 4/20 0.40
▸ MAPT P10636 6/20 0.40
▸ GAA P10253 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PKMYT1 Q99640 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ KDR P35968 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ STAT6 P42226 1/20 0.38
▸ JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173536 1.00 BTK (0.40) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL30206183 0.93 PTK2 (0.41) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL29173604 0.93 PTK2 (0.41) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL30206034 0.92 PKMYT1 (0.40) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL29173612 0.92 PKMYT1 (0.40) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL29173689 0.91 PKMYT1 (0.40) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL30206236 0.91 PKMYT1 (0.40) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL29173355 0.91 PKMYT1 (0.40) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL30206259 0.91 PKMYT1 (0.40) BTKMAPTGAASMN1; SMN2MAPK1
SCHEMBL24944396 0.91 EML4 (0.46) BTKSTAT6JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 BTK 2111/4885MAPT 4719/4885GAA 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback